Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations. | Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
9    2    0    31-10-2020